Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 18/20 | 0.52 |
| ▸ | ABHD6 | Q9BV23 | 8/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 5/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137408 | 0.86 | MGLL (0.69) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL23349094 | 0.85 | MGLL (0.56) | MGLLABHD6CYP2D6PLA2G7ENPP2 | |
| SCHEMBL20168507 | 0.85 | MGLL (0.57) | MGLL | |
| SCHEMBL20137385 | 0.82 | MGLL (0.53) | MGLLABHD6CYP2D6PLA2G7ENPP2 | |
| SCHEMBL20137403 | 0.82 | MGLL (0.58) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL20155493 | 0.82 | MGLL (0.58) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL19974295 | 0.81 | MGLL (0.53) | MGLLABHD6CYP2D6PLA2G7ENPP2 | |
| SCHEMBL17092682 | 0.81 | MGLL (0.54) | MGLLABHD6CYP2D6PLA2G7ENPP2 | |
| SCHEMBL20503441 | 0.81 | MGLL (0.54) | MGLLABHD6CYP2D6PLA2G7ENPP2 | |
| SCHEMBL18064897 | 0.80 | MGLL (0.53) | MGLLABHD6CYP2D6PLA2G7ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248947-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| EP-3541822-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2018093946-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134675-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885ABHD6 563/4885CYP2D6 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.